SBIR/STTR Research Award
Novel Single Well Avidity EIA to Determine Recency of HIV-1 Infections
Award amount
$1,000,000Program and phase
SBIR · Phase IIAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SEDIA BIOSCIENCES CORPORATION
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LB3AM53JKK33
- Solicitation number
- PA13-234
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): The objectives of this project are to develop a commercial single well HIV-1 Limiting Antigen Avidity EIA, developed in Phase I as a research tool, and establish its suitability for identifying recent HIV-1 infections on both a population an on an individual clinical basis as an aid to early intervention in acute infections. Such methods are needed for accurate measures of the incidence of new HIV infections to enable monitoring of the epidemic in populations, optimal targeting of public health resources and assessment of intervention effectiveness. In addition, identification of persons recently infected is important a these persons are typically hyper-infectious and at greater risk of transmitting the disease to partners. The scientific literature estimates that nearly half of all infections are transmitted frm partners who themselves are recent infections. Such high risk individuals should be aggressively identified treated, counseled and contact-traced to immediat
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development and Commercialization of an Innovative Rapid HIV Incidence Assay
- Development and Commercialization of an Innovative Rapid HIV-1 Incidence Assay
- Novel Single Well Avidity EIA to Determine Recency of HIV-1 Infections
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
4 SBIR/STTR records share this UEI (2012–2016). Reported award amounts total $3,181,096. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services